Intuitive Surgical jumps after Q1 beat as global da Vinci procedure growth stays strong
Intuitive Surgical shares are jumping after the company reported Q1 2026 results that beat expectations, with revenue up 23% year over year to $2.77 billion and adjusted EPS of $2.50. Procedure growth remained strong (about 14% in the U.S. and about 19% outside the U.S.), reinforcing demand momentum for da Vinci systems and recurring instruments revenue.
1. What’s driving ISRG higher today
Intuitive Surgical is rallying after posting a decisive Q1 2026 beat, highlighted by revenue of $2.77 billion (up 23% year over year) and adjusted EPS of $2.50. The print points to continued strength in the company’s high-recurring revenue model, with instruments and accessories revenue rising to $1.69 billion as procedure volumes climbed globally.
2. Demand signal: procedure growth remains robust
The quarter showed broad-based utilization momentum. U.S. da Vinci procedure growth was approximately 14%, led by general surgery (including cholecystectomy, hernia repair, and appendectomy) alongside growth in gynecology, while outside-the-U.S. procedure growth was approximately 19% with strength across general surgery, urology, and gynecology. That combination—healthy utilization plus rising recurring consumables—helped investors look past concerns that 2026 growth might decelerate versus 2025.
3. Capital returns and the quality of earnings
Share repurchases also supported per-share results during the quarter. Investors are focusing on whether the upside was driven purely by buybacks or also by underlying demand and operating performance; the strong revenue growth and procedure trends suggest the quarter’s surprise wasn’t solely financial engineering, even as repurchases likely provided an incremental lift to EPS.